Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 2c; Adjusts FY12 Outlook

Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.28, $0.02 better than the analyst estimate of $1.26. Revenue for the quarter came in at $750 million versus the consensus estimate of $788.53 million.

Sees FY2012 EPS of $5.00-$5.10, versus the consensus of $5.03. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.05 billion, versus the consensus of $3.10 billion.

For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• McDonald’s posts better-than-expected third-quarter comparable sales
• Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
• Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance